Valeant Pharmaceuticals says it will file Q1 results before deadline

Valeant Pharmaceuticals reaffirmed its first-quarter guidance on Monday and said it will fileits results for the quarter well in advance of a July 31deadline.

The Laval, Que.-based company said in a release it will file the results by June 10with the U.S. Securities and Exchange Commission and Canadian securities regulators. The end of Julydeadline is tied to an agreementwith the company's lenders.

The company also said it expects to file the results of itssecond quarter, and for subsequent quarters, on a "timely basis."

The reaffirmed guidance hasValeantexpecting to make between$1.30 to $1.55 per share for the quarter.

• Valeant restates earnings, names new board members

In late April, Valeant filed long-overdue results from 2015 asit wrestles with a number of government investigations and aplunging stock price.

• Warren Buffett calls Valeant strategy 'flawed'
• Valeant Pharmaceuticals blasted by U.S. lawmakers over drug price hikes

Shares ofValeantinitially opened higher on the NYSE and TSX on Monday morning, but subsequently retreated. On the NYSE, the stock finished lower by $1.82 at $28.07 US, while the stockwas down $2.02 at $36.56on the TSX.